Patient satisfaction after first-line treatment for localized prostate cancer (in Germany)

Posted on January 6, 2012 by Sitemaster

A new article in the journal Anticancer Research suggests that patients had greater satisfaction after modern forms of external beam radiation therapy (EBRT) than after some other standard forms of first-line treatment. Of course the absolute truth of this conclusion may be affected by the details of the study.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , | 1 Comment »

Limited value of immediate, adjuvant ADT in men with pT3b prostate cancer

Posted on February 6, 2011 by Sitemaster

New data published by clinical researchers at the Mayo Clinic have suggested that there is no overall survival benefit associated with adjuvant hormone therapy after surgery in men with pathological T3b disease.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 9 Comments »

Neoadjuvant hormone therapy for patients undergoing first-line radiation therapy

Posted on September 21, 2010 by Sitemaster

The Irish Clinical Oncology Research Group trial 97-01 was a randomized clinical trial designed to compare the long-term outcomes of patients treated with either 4 months or 8 months of hormonal therapy given before external beam radiotherapy for localized prostate cancer.

Filed under: Management, Treatment | Tagged: , , , , | Leave a Comment »

The long-term survival of patients with metastatic prostate cancer

Posted on July 8, 2010 by Sitemaster

In the late 1980s and early 1990s it was generally considered that men diagnosed with metastatic (but still hormone sensitive) prostate cancer had an estimated survival of 18 to 36 months from the time of diagnosis — including their time on treatment with hormonal therapy.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , | 6 Comments »

Sunday at the ASCO annual meeting

Posted on June 6, 2010 by Sitemaster

There were a number of significant prostate cancer presentations today, and while none of them were “game changing” (for a variety of reasons), they are certainly worthy of notice.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 2 Comments »

Relapse-free survival of non-metastatic patients treated with primary androgen deprivation

Posted on April 27, 2010 by Sitemaster

Many patients with no specific evidence of metastatic disease now receive primary androgen deprivation therapy (PADT) much earlier than was the case before the availability of the PSA test. This includes patients who get hormone therapy for a rising PSA after other forms of first-line therapy and patients who receive hormone therapy as their first-line [...]

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , | 4 Comments »

Hormone therapy effective in man with PSA > 21,000, but …

Posted on March 22, 2010 by Sitemaster

An article in just published in Onkologie reports the diagnosis and (short-term) treatment of widely disseminated, metastatic prostate cancer in a 64-year-old Croatian man with a PSA of > 21,000 ng/ml.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , | 4 Comments »

Short-term ADT with RT for localized prostate cancer

Posted on March 6, 2010 by Sitemaster

The RTOG 94-08 clinical trial was designed to test the idea that just 4 months of hormone therapy, administered  before and during radiation therapy, would improved the overall survival of patients diagnosed with clinical stage T1b-T2b prostate cancer and a PSA level equal to or lower than 20 ng/ml.

Filed under: Management, Treatment | Tagged: , , , , | 1 Comment »

Prostate cancer news report: Sunday, January 24, 2010

Posted on January 24, 2010 by Sitemaster

In this weekend’s prostate cancer news reports, we have addressed recent publications on: A SNP that may be specifically linked to risk for prostate cancer in African Americans The need for extended biopsies in men with larger prostates who are considering focal treatment for prostate cancer A possible association between diabetes, race, obesity, and risk [...]

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , , , , , , , , , , , | Leave a Comment »

Prostate cancer news reports: Wednesday, January 13, 2010

Posted on January 13, 2010 by Sitemaster

Today’s news reports summarize papers recently published on: Optimism, pessimism, and long-term health outcomes External beam radiation + hormone therapy for high-risk patients Quality of life and health utility after radical prostatectomy Paclitaxel + estradiol combination therapy in men progressing after docetaxel-based chemotherapy

Filed under: Management, Living with Prostate Cancer, Treatment, Drugs in development | Tagged: , , , , , , , , , , | Leave a Comment »

Hormone therapy not helpful for low-risk patients receiving first-line radiation

Posted on November 3, 2009 by Sitemaster

A report presented yesterday in Chicago, at the annual meeting of the American Society for Radiation Oncology (ASTRO), suggests that short-term hormone therapy given prior to and during first-line radiation treatment to intermediate-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation alone. However, the same study also showed [...]

Filed under: Management, Treatment | Tagged: , , , , | Leave a Comment »

Prostate cancer news reports: Wednesday, September 23, 2009

Posted on September 23, 2009 by Sitemaster

Today’s news reports cover items on: Extent and number of biopsy cores and eligibility for active surveillance Intermittent vs. complete androgen deprivation Hormone therapy and risk for cardiovascular disease and death Surrogate markets for disease progression in men with CRPC

Filed under: Diagnosis, Management, Risk, Treatment | Tagged: , , , , , , , , , , , , | Leave a Comment »

Adding hormone therapy to brachytherapy: what works best?

Posted on September 15, 2009 by Sitemaster

A recent report in the International Journal of Radiation Oncology • Biology • Physics suggests that the type of hormone therapy used in combination with brachytherapy for treatment of localized prostate cancer makes no difference to the patients’ long-term outcomes.

Filed under: Management, Treatment | Tagged: , , | Leave a Comment »

Hormone therapy, radiotherapy, and risk for cardiovascular mortality

Posted on August 27, 2009 by Sitemaster

An article in this week’s Journal of the American Medical Association has gained a great deal of media attention because it links hormone therapy in prostate cancer patients to a risk for death in patients with pre-existing cardiovascular disorders. The “New” Prostate Cancer InfoLink feels that it should emphasize that the outcomes reported in this study are [...]

Filed under: Management, Treatment | Tagged: , , , , | Leave a Comment »

Prostate cancer news reports: Thursday, July 16, 2009

Posted on July 16, 2009 by Sitemaster

Today’s news reports include items on: Exercise and prostate cancer risk (in mice) Quality of life over 4 years after first-line therapy The adverse effects of long-term hormone therapy

Filed under: Living with Prostate Cancer, Management, Prevention, Treatment, Uncategorized | Tagged: , , , , | Leave a Comment »

Next Page »
Follow

Get every new post delivered to your Inbox.

Join 269 other followers